Semaglutide and tirzepatide are the two most-researched incretin peptides in metabolic science. The core difference: semaglutide targets one receptor (GLP-1), while tirzepatide is a dual agonist that engages both GIP and GLP-1 receptors.
Semaglutide in research
Semaglutide is a long-acting GLP-1 receptor agonist, among the most extensively studied compounds in glycemic, metabolic, and appetite-regulation research.
Tirzepatide in research
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a “twincretin” — studied for the combined incretin action of engaging two receptor pathways at once.
Key research differences
| Receptor targets | Semaglutide: GLP-1 · Tirzepatide: GIP + GLP-1 |
|---|---|
| Class | Semaglutide: single agonist · Tirzepatide: dual agonist |
| Research area | Both: metabolic, glycemic, appetite-regulation models |
Researchers studying next-generation multi-receptor agonists also compare these with retatrutide (triple agonist) — see Retatrutide vs Tirzepatide.
Shop TirzepatideShop Semaglutide
Why researchers buy from Miami Peptide Lab
- 99%+ purity, lab-tested every lot — COA available on request
- Ships from Miami / the US in 24–48h, discreet cold-chain packaging
- Buy-more-save-more bundle pricing, and a reship-or-refund guarantee
Research Use Only. All compounds are sold strictly for laboratory research and are not for human or animal consumption, nor for therapeutic, diagnostic, or cosmetic use.
